What is Sermorelin?
Sermorelin is a synthetic 29-amino acid peptide representing the biologically active N-terminal fragment of endogenous growth hormone releasing hormone (GHRH 1-44). Its full chemical name is GHRH(1-29)-NH2.
It was developed in the 1980s and received FDA approval for pediatric GH deficiency (sold as Geref by Serono). After the brand was discontinued in 2002, sermorelin became one of the most widely compounded peptide therapies in the United States and continues to be prescribed by anti-aging and longevity clinics.
The key distinction from exogenous HGH: sermorelin does not deliver growth hormone. It signals the pituitary gland to produce and release GH through the body's existing machinery, preserving normal somatostatin-mediated feedback control.
Mechanism of Action
Sermorelin binds to GHRH receptors (GHRHR) on pituitary somatotroph cells. This binding activates adenylyl cyclase via Gs-coupled signaling, raising intracellular cAMP. The result is a two-part effect: immediate GH release from existing secretory granules, and stimulation of new GH synthesis over hours.
Natural Pulse Preservation
Unlike exogenous HGH, which raises serum GH independently of pituitary output, sermorelin works within the natural hypothalamic-pituitary axis. Somatostatin (SRIH) continues to modulate GH release, which means GH levels cannot exceed the physiological ceiling set by the body's own feedback system. This is the primary safety advantage over exogenous HGH.
GH Pulse Timing
The pituitary releases GH in discrete pulses, with the largest pulse occurring approximately 60-90 minutes after sleep onset during the first slow-wave sleep cycle. Sermorelin amplifies this natural pulse rather than creating a continuous GH elevation, which is closer to the physiological pattern associated with youth and favorable body composition.
Sermorelin vs Exogenous HGH
| Factor | Sermorelin | Exogenous HGH |
|---|---|---|
| Mechanism | Stimulates pituitary GH release | Delivers GH directly |
| Pituitary feedback | Preserved (somatostatin still active) | Suppressed over time |
| GH pulse pattern | Physiological pulsatile | Continuous elevation |
| Peak GH output | Lower; limited by pituitary reserve | Dose-dependent, uncapped |
| Acromegaly risk | Very low at normal doses | Dose-dependent risk |
| Endogenous GH axis | Maintained or improved | Suppressed with chronic use |
| Cost (approx.) | $100-250/month (compounded) | $500-1,500+/month |
| Regulatory status (US) | Compounded; no Rx indication | Schedule III controlled |
| IGF-1 elevation | Moderate, dose-dependent | Significant elevation |
The tradeoff is ceiling vs control. Exogenous HGH can drive IGF-1 and GH to supraphysiological levels that sermorelin cannot reach. But sermorelin's preserved feedback system means researchers can run it longer with a lower risk profile, and the pituitary continues to function normally rather than atrophying from disuse.
Sermorelin Dosage Protocols
Standard Bedtime Protocol (Most Common)
The single most common sermorelin protocol in research and compounding settings is a single injection at bedtime:
Bedtime-Only Protocol
- Dose: 200-500 mcg subcutaneous
- Timing: 30-60 minutes before sleep, in a fasted state (no carbohydrates or insulin-spiking food for 2 hours prior)
- Site: Abdomen, upper thigh, or deltoid area
- Rationale: Amplifies the largest natural GH pulse, which peaks during the first slow-wave sleep cycle
Twice-Daily Protocol
Some protocols add a morning injection for sustained IGF-1 elevation:
Twice-Daily Protocol
- Morning dose: 100-200 mcg fasted, first thing in the morning
- Bedtime dose: 200-300 mcg (as above)
- Total daily: 300-500 mcg split across two injections
- Best for: Body composition goals, higher IGF-1 targets, or when combined with ipamorelin
Dosage by Goal
| Goal | Typical Dose | Frequency | Notes |
|---|---|---|---|
| Anti-aging / longevity | 200-300 mcg | Once daily (bedtime) | Conservative entry; good for most researchers |
| Sleep and recovery | 200-300 mcg | Once daily (bedtime) | Sleep quality often the first noticeable effect |
| Body composition | 300-500 mcg | Once or twice daily | Stack with ipamorelin for synergistic effect |
| GH deficiency research | 300-500 mcg | Once daily (bedtime) | Monitor IGF-1 at 8-12 weeks |
Fasting Requirement
Insulin blunts GH release at the pituitary level. Elevated blood glucose or insulin at the time of injection substantially reduces the GH pulse sermorelin would otherwise trigger. The 2-hour fasted window before bedtime injection is not optional if optimizing for GH output.
The Sermorelin and Ipamorelin Stack
This is the most studied and widely used GHRH/GHRP combination in compounding medicine. The synergy is mechanistic, not additive in the simple sense.
Why They Work Together
Sermorelin acts on GHRH receptors to increase GH pulse amplitude. Ipamorelin acts on ghrelin receptors (GHSR-1a) to both amplify GH pulse release and mildly inhibit somatostatin activity at the hypothalamic level. The two complementary mechanisms produce a GH secretion response that research consistently shows is 2-5x greater than either compound alone at equivalent doses.
Stack Protocol
Sermorelin + Ipamorelin (Bedtime)
- Sermorelin: 200-300 mcg subcutaneous, 30-60 minutes before sleep (fasted)
- Ipamorelin: 200-300 mcg subcutaneous, same injection window
- Combined in one syringe? Yes, if both are reconstituted separately in bacteriostatic water and drawn into one syringe immediately before injection. Stability data supports same-syringe administration for short periods.
- Timing relative to food: Same fasting requirement as sermorelin alone
Sermorelin + CJC-1295 Alternative
CJC-1295 (with DAC) is a longer-acting GHRH analog with a multi-day half-life. Some researchers prefer it over sermorelin for once-weekly or twice-weekly injection schedules. However, CJC-1295 DAC produces a sustained GH bleed rather than discrete pulses, which some researchers consider less physiological. Sermorelin's short half-life (~10-12 minutes) means it closely mimics natural GHRH pulse release, which is considered a feature, not a limitation. For pulse-preserving GH optimization, sermorelin is the preferred GHRH component.
Cycle Length and Timing
Typical Research Duration
Most clinical protocols for adult GH optimization run sermorelin for a minimum of 3-6 months before assessing results. IGF-1 levels, sleep quality, body composition, and skin texture are the primary outcome markers. Short cycles of 4-8 weeks are unlikely to produce meaningful IGF-1 changes.
| Timeframe | Expected Changes |
|---|---|
| Weeks 1-4 | Improved sleep quality, reduced sleep latency; some researchers notice more vivid dreaming |
| Weeks 4-8 | Energy improvement, early body composition shifts; mild IGF-1 elevation measurable on labs |
| Months 3-6 | Meaningful IGF-1 elevation, body fat changes, improved skin elasticity, joint comfort improvement |
| 6+ months | Cumulative benefits plateau; some protocols cycle off for 1-2 months then restart |
Continuous vs Cycled Protocols
Unlike anabolic steroids, sermorelin does not suppress the endogenous GH axis during use -- it stimulates it. Many clinical sermorelin programs run continuously for 12 months or longer. Cycling protocols (e.g., 5 days on, 2 days off) are used in some research designs to prevent GHRH receptor downregulation, though the clinical significance of receptor desensitization at standard sermorelin doses is debated. A practical approach is 5-on/2-off or continuous with a 4-week break at month 6.
Side Effects and Safety Profile
Clinical Safety Record
Sermorelin has an unusually well-documented safety record by peptide research standards, owing to the FDA clinical trial history for pediatric GH deficiency. The trials showed it was well-tolerated over years of daily use in children, a more sensitive population than adults.
Common Side Effects
- Injection site reactions -- redness, mild swelling, soreness. Most common in first 2-4 weeks; typically resolves with rotation of sites.
- Flushing or warmth -- reported in 5-10% of users, usually within 30 minutes of injection. Transient.
- Headache -- mild, typically early in a cycle. Often resolves within 2-3 weeks.
- Water retention -- mild, especially at higher doses. Joint fullness and slight scale weight increase common in first 4 weeks.
- Fatigue or grogginess -- occasionally reported after bedtime doses, likely a GH-mediated deep sleep effect. Generally resolves as sleep quality improves.
Rare or Dose-Dependent Effects
- Elevated IGF-1 -- at high doses or in combination with ipamorelin, IGF-1 can rise meaningfully. Monitoring IGF-1 at 8-12 week intervals is standard practice in clinical settings.
- Carpal tunnel symptoms -- more common with exogenous HGH; reported occasionally with sermorelin at high doses due to water retention.
- Glucose sensitivity -- GH is counter-regulatory to insulin. Some researchers see mild fasting glucose increases, particularly at doses over 400 mcg. Monitoring is appropriate in pre-diabetic subjects.
Sermorelin vs Related Peptides
| Peptide | Class | Half-life | GH Mechanism | Best Use Case |
|---|---|---|---|---|
| Sermorelin | GHRH analog | ~10-12 min | GHRH receptor (pituitary) | Anti-aging, GH optimization, sleep |
| CJC-1295 (DAC) | GHRH analog (long-acting) | 6-8 days | GHRH receptor (pituitary) | Infrequent injection schedules |
| Ipamorelin | GHRP (selective) | ~2 hours | GHSR-1a (ghrelin receptor) | Selective GH pulse; stack with GHRH |
| GHRP-6 | GHRP (non-selective) | ~2 hours | GHSR-1a + cortisol/prolactin | Higher GH at cost of cortisol elevation |
| MK-677 (Ibutamoren) | GH secretagogue (oral) | 24 hours | GHSR-1a (oral bioavailability) | Oral route; sleep and IGF-1 elevation |
Frequently Asked Questions
Does sermorelin need to be refrigerated?
Lyophilized (freeze-dried) sermorelin is stable at room temperature, but most compounding pharmacies ship it refrigerated for maximum stability. After reconstitution with bacteriostatic water, reconstituted sermorelin should be refrigerated at 2-8°C and used within 30 days. Do not freeze reconstituted product. Keep away from light.
Can women use sermorelin?
Yes. The GH axis physiology is similar in men and women and sermorelin has been studied in both. Women naturally have higher GH pulse frequency and somewhat higher baseline IGF-1 than age-matched men, so optimal doses may be slightly lower. Women with perimenopause-related GH axis decline are a common population in compounding clinic protocols. See our peptides for women guide for a broader overview.
How long before sermorelin shows results?
Sleep quality improvements are typically the first sign, often appearing within 2-4 weeks. Body composition changes take longer -- most researchers report noticeable lean mass and fat loss changes at 3-4 months. IGF-1 elevation on labs typically becomes measurable at the 6-8 week mark. Skin and hair changes, if they occur, are a 4-6 month outcome.
What time of day should sermorelin be injected?
Bedtime is the near-universal recommendation for single-injection protocols. The rationale is that the largest natural GH pulse occurs during the first slow-wave sleep cycle, and sermorelin amplifies this existing pulse. A pre-sleep injection times the peak GHRH signal to coincide with the body's existing GH release trigger. Food should be avoided for 2 hours before the injection to prevent insulin-mediated GH blunting.
Is sermorelin legal?
Sermorelin's regulatory status varies by country. In the United States, it exists in a compounding pharmacy gray zone: it is not FDA-approved for adult use but has been compounded by licensed pharmacies under 503A regulations. As of 2025-2026, FDA has placed some GHRH analogs on the "difficult to compound" list, which affects availability through certain channels. Researchers should verify current regulatory status in their jurisdiction before sourcing.